Pregnancy outcome following in utero exposure to hydroxychloroquine: A prospective comparative observational study

Reproductive Toxicology

Volumn 39, Issue , 2013, Pages 58-62

  Diav Citrin, Orna ^a,b   Blyakhman, Shani ^c   Shechtman, Svetlana ^a   Ornoy, Asher ^a,b  

^a MINISTRY OF HEALTH   (Israel)

^b HEBREW UNIVERSITY   (Israel)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Congenital anomalies; Hydroxychloroquine; Pregnancy; Rheumatologic diseases

Indexed keywords

HYDROXYCHLOROQUINE;

ADULT; ARTICLE; BIRTH WEIGHT; COMPARATIVE STUDY; CONGENITAL DISORDER; CONTROLLED STUDY; DELIVERY; DRUG SAFETY; FEMALE; FIRST TRIMESTER PREGNANCY; FOLLOW UP; GESTATIONAL AGE; HUMAN; INFANT; ISRAEL; LUPUS ERYTHEMATOSUS; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PATIENT COUNSELING; PREGNANCY OUTCOME; PREMATURE LABOR; PRENATAL DRUG EXPOSURE; PROSPECTIVE STUDY; RHEUMATIC DISEASE;

ABNORMALITIES, DRUG-INDUCED; ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIRTH WEIGHT; CROHN DISEASE; FEMALE; GESTATIONAL AGE; HUMANS; HYDROXYCHLOROQUINE; INFANT, NEWBORN; ISRAEL; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PREGNANCY; PREGNANCY OUTCOME; PROSPECTIVE STUDIES;

EID: 84877795901     PISSN: 08906238     EISSN: 18731708     Source Type: Journal    
DOI: 10.1016/j.reprotox.2013.04.005     Document Type: Article

References (34)

1. Rynes R.I. Antimalarial drugs in the treatment of rheumatological diseases. British Journal of Rheumatology 1997, 36:799-805.
2. Costedoat-Chalumeau N., Amoura Z., Aymard G., Le T.H., Wechsler B., Vauthier D., et al. Evidence of transplacental passage of hydroxychloroquine in humans. Arthritis and Rheumatism 2002, 46:1123-1124.
3. Udalova L.D. The effect of chloroquine on the embryonal development of rats. Pharmacology and Toxicology [Russian] 1967, 2:226-228. [cited in Shepard].
4. Ullberg S., Lindquist N.G., Sjöstrand S.E. Accumulation of chorio-retinotoxic drugs in the foetal eye. Nature 1970, 227:1257-1258.
5. Paufique L., Magnard P. Retinal degeneration in 2 children following preventive antimalarial treatment of the mother during pregnancy. Bulletin of the Society of Ophthalmology of France (In French: Bulletin des societes d'ophtalmologie de France) 1969, 69:466-467.
6. Hart C.W., Naunton R.F. The ototoxicity of chloroquine phosphate. Archives of Otolaryngology 1964, 80:407-412.
7. Wolfe M.S., Cordero J.F. Safety of chloroquine in chemosuppression of malaria during pregnancy. British Medical Journal (Clinical Research Ed.) 1985, 290:1466-1467.
8. McGready R., Thwai K.L., Cho T., Samuel, Looareesuwan S., White N.J., et al. The effects of quinine and chloroquine antimalarial treatments in the first trimester of pregnancy. Transactions of the Royal Society of Tropical Medicine and Hygiene 2002, 96:180-184.
9. Kayentao K., Kodio M., Newman R.D., Maiga H., Doumtabe D., Ongoiba A., et al. Comparison of intermittent preventive treatment with chemoprophylaxis for the prevention of malaria during pregnancy in Mali. Journal of Infectious Diseases 2005, 191:109-116.
10. Parke A.L. Antimalarial drugs, systemic lupus erythematosus and pregnancy. Journal of Rheumatology 1988, 15:607-610.
11. Parke A. Antimalarial drugs and pregnancy. American Journal of Medicine 1988, 85:30-33.
12. Levy M., Buskila D., Gladman D.D., Urowitz M.B., Koren G. Pregnancy outcome following first trimester exposure to chloroquine. American Journal of Perinatology 1991, 8:174-178.
13. Buchanan N.M., Toubi E., Khamashta M.A., Lima F., Kerslake S., Hughes G.R. Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases. Annals of the Rheumatic Diseases 1996, 55:486-488.
14. Parke A., West B. Hydroxychloroquine in pregnant patients with systemic lupus erythematosus. Journal of Rheumatology 1996, 23:1715-1718.
15. Motta M., Tincani A., Faden D., Zinzini E., Lojacono A., Marchesi A., et al. Follow-up of infants exposed to hydroxychloroquine given to mothers during pregnancy and lactation. Journal of Perinatology 2005, 25:86-89.
16. Klinger G., Morad Y., Westall C.A., Laskin C., Spitzer K.A., Koren G., et al. Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases. Lancet 2001, 358:813-814. [letter].
17. Cimaz R., Brucato A., Meregalli E., Muscará M., Sergi P. Electroretinograms of children born to mothers treated with hydroxychloroquine during pregnancy and breast-feeding: comment on the article by Costedoat-Chalumeau et al. Arthritis and Rheumatism 2004, 50:3056-3057. [letter].
18. Renault F., Flores-Guevara R., Renaud C., Richard P., Vermersch A.I., Gold F. Visual neurophysiological dysfunction in infants exposed to hydroxychloroquine in utero. Acta Paediatrica 2009, 98:1500-1503.
19. Ingster-Moati I., Albuisson E. Visual neurophysiological dysfunction in infants exposed to hydroxychloroquine in utero. Acta Paediatrica 2010, 99:4. [letter].
20. Renault F., Flores-Guevara R. RE: visual neurophysiological dysfunction in infants exposed to hydroxychloroquine in utero. Acta Paediatrica 2010, 99:4-5. [letter].
21. Frassi M., Biasini C., Taglietti M., Danieli E., Faden D., Lojacono A. Hydroxychloroquine in pregnant patients with rheumatic disease: a case control observation of 76 treated pregnancies. Lupus 2004, 13:755. [abstract].
22. Levy R.A., Vilela V.S., Cataldo M.J., Ramos R.C., Duarte J.L., Tura B.R., et al. Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus 2001, 10:401-404.
23. Costedoat-Chalumeau N., Amoura Z., Duhaut P., Huong D.L., Sebbough D., Wechsler B., et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. Arthritis and Rheumatism 2003, 48:3207-3211.
24. Clowse M.E., Magder L., Witter F., Petri M. Hydroxychloroquine in lupus pregnancy. Arthritis and Rheumatism 2006, 54:3640-3647.
25. Sperber K., Hom C., Chao C.P., Shapiro D., Ash J. Pediatric Rheumatology Online Journal 2009, 7:9.
26. Mok C.C., Wong R.W.S. Pregnancy in systemic lupus erythematosus. Postgraduate Medical Journal 2001, 77:157-165.
27. Clowse M.E. Lupus activity in pregnancy. Rheumatic Diseases Clinics of North America 2007, 33:237-252.
28. Holmes L.B. Need for inclusion and exclusion criteria for the structural abnormalities recorded in children born from exposed pregnancies. Teratology 1999, 59:1-2. [Editorial].
29. Petri M. Systemic lupus erythematosus and pregnancy. Rheumatic Diseases Clinics of North America 1994, 20:87-118.
30. Lockshin M.D. Lupus pregnancy. Clinics in Rheumatic Diseases 1985, 11:611-632.
31. Mintz G., Niz J., Gutierrez G., Garcia-Alfonso A., Karchmer S. Prospective study of pregnancy in systemic lupus erythematosus. Results of a multidisciplinary approach. Journal of Rheumatology 1986, 13:732-739.
32. Nossent H.C., Swaak T.J. Systemic lupus erythematosus. VI. Analysis of the interrelationship with pregnancy. Journal of Rheumatology 1990, 17:771-776.
33. Petri M., Allbritton J. Fetal outcome of lupus pregnancy: a retrospective case-control study of the Hopkins Lupus Cohort. Journal of Rheumatology 1993, 20:650-656.
34. Lockshin M.D., Reinitz E., Druzin M.L., Murrman M., Estes D. Lupus pregnancy. Case-control prospective study demonstrating absence of lupus exacerbation during or after pregnancy. American Journal of Medicine 1984, 77:893-898.